<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VIGAMOX  - moxifloxacin hydrochloride solution </strong><br>REMEDYREPACK INC. <br></p></div>
<h1>These highlights do not include all the information needed to use VIGAMOX® Solution safely and effectively. See full prescribing information for VIGAMOX® Solution.VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5% as baseSterile topical ophthalmic solutionInitial U.S. Approval 1999</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<p class="First"></p>
<p>VIGAMOX® solution is indicated for the treatment of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms:</p>
<p><span class="Italics">Corynebacterium </span>species*<br><span class="Italics">Micrococcus luteus*<br></span><span class="Italics">Staphylococcus aureus<br></span><span class="Italics">Staphylococcus epidermidis<br></span><span class="Italics">Staphylococcus haemolyticus<br></span><span class="Italics">Staphylococcus hominis<br></span><span class="Italics">Staphylococcus warneri*<br></span><span class="Italics">Streptococcus pneumoniae<br></span><span class="Italics">Streptococcus viridans </span>group<br><span class="Italics">Acinetobacter lwoffii*<br></span><span class="Italics">Haemophilus influenzae<br></span><span class="Italics">Haemophilus parainfluenzae*<br></span><span class="Italics">Chlamydia trachomatis</span></p>
<p>*Efficacy for this organism was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<p class="First"></p>
<p>Instill one drop in the affected eye 3 times a day for 7 days.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1>DOSAGE FORMS &amp; STRENGTHS</h1>
<p class="First"></p>
<p>4 mL bottle filled with 3 mL sterile ophthalmic solution of moxifloxacin hydrochloride, 0.5% as base.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"></p>
<p>VIGAMOX® solution is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to moxifloxacin, to other quinolones, or to any of the components in this medication.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>WARNINGS AND PRECAUTIONS</h1>
<p class="First"></p>
<p>
 
</p>
<p></p>
<p>NOT FOR INJECTION. VIGAMOX® solution is for topical ophthalmic use only and should not be injected subconjunctivally or introduced directly into the anterior chamber of the eye.</p>
<p>
 
</p>
<p></p>
<p>In patients receiving systemically administered quinolones, including moxifloxacin, serious and occasionally fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic) reactions have been reported, some following the first dose. Some reactions were accompanied by <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (including laryngeal, pharyngeal or facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>), airway obstruction, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>. If an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to moxifloxacin occurs, discontinue use of the drug. Serious acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> may require immediate emergency treatment. Oxygen and airway management should be administered as clinically indicated.</p>
<p>
 
</p>
<p></p>
<p>As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit-lamp biomicroscopy, and, where appropriate, fluorescein staining.</p>
<p>
 
</p>
<p></p>
<p>Patients should be advised not to wear contact lenses if they have signs or symptoms of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"></p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The most frequently reported ocular adverse events were <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, decreased visual acuity, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, <span class="product-label-link" type="condition" conceptid="372912" conceptname="Visual discomfort">ocular discomfort</span>, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">ocular hyperemia</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span>, ocular <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="378756" conceptname="Conjunctival hemorrhage">subconjunctival hemorrhage</span>, and tearing. These events occurred in approximately 1-6% of patients.</p>
<p>Nonocular adverse events reported at a rate of 1-4% were <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, increased <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>DRUG INTERACTIONS</h1>
<p class="First"></p>
<p>Drug-drug interaction studies have not been conducted with VIGAMOX® solution. <span class="Italics">In vitro </span>studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>USE IN SPECIFIC POPULATIONS</h1>
<p class="First"></p>
<p>Pregnancy Category C.<br>Teratogenic Effects: Moxifloxacin was not teratogenic when administered to pregnant rats during organogenesis at oral doses as high as 500 mg/kg/day (approximately 21,700 times the highest recommended total daily human ophthalmic dose); however, decreased fetal body weights and slightly delayed fetal skeletal development were observed. There was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> when pregnant Cynomolgus monkeys were given oral doses as high as 100 mg/kg/day (approximately 4,300 times the highest recommended total daily human ophthalmic dose). An increased incidence of smaller fetuses was observed at 100 mg/kg/day.</p>
<p>Since there are no adequate and well-controlled studies in pregnant women, VIGAMOX® solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>
 
</p>
<p></p>
<p>Moxifloxacin has not been measured in human milk, although it can be presumed to be excreted in human milk. Caution should be exercised when VIGAMOX® solution is administered to a nursing mother.</p>
<p>
 
</p>
<p></p>
<p>The safety and effectiveness of VIGAMOX® solution in infants below 1 year of age have not been established.</p>
<p>There is no evidence that the ophthalmic administration of VIGAMOX® solution has any effect on weight bearing joints, even though oral administration of some quinolones has been shown to cause <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in immature animals.</p>
<p>
 
</p>
<p></p>
<p>No overall differences in safety and effectiveness have been observed between elderly and younger patients.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-9"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"></p>
<p>VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5% is a sterile solution for topical ophthalmic use. Moxifloxacin hydrochloride is an 8-methoxy fluoroquinolone anti-infective, with a diazabicyclononyl ring at the C7 position.</p>
<p><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=750fd60e-c0c4-4f32-8301-6baa3516aef2&amp;name=MM1.jpg"></p>
<p>Chemical Name:<br>1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolol[3,4-b]pyridin-6-yl]-4-oxo-3-quinoline carboxylic acid, monohydrochloride. Moxifloxacin hydrochloride is a slightly yellow to yellow crystalline powder. Each mL of VIGAMOX® solution contains 5.45 mg moxifloxacin hydrochloride, equivalent to 5 mg moxifloxacin base.</p>
<p><span class="Bold">Contains: Active: </span>Moxifloxacin 0.5% (5 mg/mL); <span class="Bold">Inactives: </span>Boric acid, sodium chloride, and purified water. May also contain hydrochloric acid/sodium hydroxide to adjust pH to approximately 6.8.</p>
<p>VIGAMOX® solution is an isotonic solution with an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of approximately 290 mOsm/kg.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-10"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<p>
 
</p>
<p></p>
<p>Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs <span class="Italics">(See <a href="#ID_14423d72-7562-f358-9b51-a15e6c43933e">12.4 Microbiology</a>)</span>.</p>
<p>
 
</p>
<p></p>
<p>Plasma concentrations of moxifloxacin were measured in healthy adult male and female subjects who received bilateral topical ocular doses of VIGAMOX® solution 3 times a day. The mean steady-state C<span class="Sub">max</span> (2.7 ng/mL) and estimated daily exposure AUC (45 ng•hr/mL) values were 1,600 and 1,000 times lower than the mean C<span class="Sub">max</span> and AUC reported after therapeutic 400 mg doses of moxifloxacin. The plasma half-life of moxifloxacin was estimated to be 13 hours.</p>
<p>
 
</p>
<p></p>
<p>The antibacterial action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.</p>
<p>The mechanism of action for quinolones, including moxifloxacin, is different from that of macrolides, aminoglycosides, or tetracyclines. Therefore, moxifloxacin may be active against pathogens that are resistant to these antibiotics and these antibiotics may be active against pathogens that are resistant to moxifloxacin. There is no cross-resistance between moxifloxacin and the aforementioned classes of antibiotics. Cross resistance has been observed between systemic moxifloxacin and some other quinolones.</p>
<p><span class="Italics">In vitro </span>resistance to moxifloxacin develops via multiple-step mutations. Resistance to moxifloxacin occurs <span class="Italics">in vitro </span>at a general frequency of between 1.8 x 10<span class="Sup">-9</span> to &lt; 1 x 10<span class="Sup">-11</span> for Gram-positive bacteria.</p>
<p>Moxifloxacin has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics">in vitro </span>and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <a href="#splSectionIndicationsUsage">INDICATIONS AND USAGE</a> section:</p>
<p><span class="Bold">Aerobic Gram-positive microorganisms:<br></span><span class="Italics">Corynebacterium </span>species*<br><span class="Italics">Micrococcus luteus*<br></span><span class="Italics">Staphylococcus aureus<br></span><span class="Italics">Staphylococcus epidermidis<br></span><span class="Italics">Staphylococcus haemolyticus<br></span><span class="Italics">Staphylococcus hominis<br></span><span class="Italics">Staphylococcus warneri*<br></span><span class="Italics">Streptococcus pneumoniae<br></span><span class="Italics">Streptococcus viridans </span>group</p>
<p><span class="Bold">Aerobic Gram-negative microorganisms:<br></span><span class="Italics">Acinetobacter lwoffii*<br></span><span class="Italics">Haemophilus influenzae<br></span><span class="Italics">Haemophilus parainfluenzae*</span></p>
<p><span class="Bold">Other microorganisms:<br></span><span class="Italics">Chlamydia trachomatis</span></p>
<p>*Efficacy for this organism was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p>The following <span class="Italics">in vitro </span>data are also available, <span class="Bold">but their clinical significance in ophthalmic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> is unknown. </span>The safety and effectiveness of VIGAMOX® solution in treating ophthalmological <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established in adequate and well-controlled trials.</p>
<p>The following organisms are considered susceptible when evaluated using systemic breakpoints. However, a correlation between the <span class="Italics">in vitro </span>systemic breakpoint and ophthalmological efficacy has not been established. The list of organisms is provided as guidance only in assessing the potential treatment of conjunctival <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Moxifloxacin exhibits <span class="Italics">in vitro </span>minimal inhibitory concentrations (MICs) of 2 μg/ml or less (systemic susceptible breakpoint) against most (≥ 90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following ocular pathogens.</p>
<p><span class="Bold">Aerobic Gram-positive microorganisms:<br></span><span class="Italics">Listeria monocytogenes<br></span><span class="Italics">Staphylococcus saprophyticus<br></span><span class="Italics">Streptococcus agalactiae<br></span><span class="Italics">Streptococcus mitis<br></span><span class="Italics">Streptococcus pyogenes<br></span><span class="Italics">Streptococcus </span>Group C, G and F</p>
<p><span class="Bold">Aerobic Gram-negative microorganisms:<br></span><span class="Italics">Acinetobacter baumannii<br></span><span class="Italics">Acinetobacter calcoaceticus<br></span><span class="Italics">Citrobacter freundii<br></span><span class="Italics">Citrobacter koseri<br></span><span class="Italics">Enterobacter aerogenes<br></span><span class="Italics">Enterobacter cloacae<br></span><span class="Italics">Escherichia coli<br></span><span class="Italics">Klebsiella oxytoca<br></span><span class="Italics">Klebsiella pneumoniae<br></span><span class="Italics">Moraxella catarrhalis<br></span><span class="Italics">Morganella morganii<br></span><span class="Italics">Neisseria gonorrhoeae<br></span><span class="Italics">Proteus mirabilis<br></span><span class="Italics">Proteus vulgaris<br></span><span class="Italics">Pseudomonas stutzeri</span></p>
<p><span class="Bold">Anaerobic microorganisms:<br></span><span class="Italics">Clostridium perfringens<br></span><span class="Italics">Fusobacterium </span>species<br><span class="Italics">Prevotella </span>species<br><span class="Italics">Propionibacterium <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span></span></p>
<p><span class="Bold">Other microorganisms:<br></span><span class="Italics">Chlamydia pneumoniae<br></span><span class="Italics">Legionella pneumophila<br></span><span class="Italics">Mycobacterium avium<br></span><span class="Italics">Mycobacterium marinum<br></span><span class="Italics">Mycoplasma pneumoniae</span></p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-11"></a><p></p>
<h1>NONCLINICAL TOXICOLOGY</h1>
<p class="First"></p>
<p>Long-term studies in animals to determine the carcinogenic potential of moxifloxacin have not been performed. However, in an accelerated study with initiators and promoters, moxifloxacin was not carcinogenic in rats following up to 38 weeks of oral dosing at 500 mg/kg/day (approximately 21,700 times the highest recommended total daily human ophthalmic dose for a 50 kg person, on a mg/kg basis).</p>
<p>Moxifloxacin was not mutagenic in four bacterial <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> used in the Ames <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> </span>reversion assay. As with other quinolones, the positive response observed with moxifloxacin in <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA 102 using the same assay may be due to the inhibition of DNA gyrase. Moxifloxacin was not mutagenic in the CHO/HGPRT mammalian cell gene mutation assay. An equivocal result was obtained in the same assay when v79 cells were used. Moxifloxacin was clastogenic in the v79 chromosome aberration assay, but it did not induce unscheduled DNA synthesis in cultured rat hepatocytes. There was no evidence of genotoxicity <span class="Italics">in vivo </span>in a micronucleus test or a dominant lethal test in mice.</p>
<p>Moxifloxacin had no effect on fertility in male and female rats at oral doses as high as 500 mg/kg/day, approximately 21,700 times the highest recommended total daily human ophthalmic dose. At 500 mg/kg orally there were slight effects on sperm morphology (head-tail separation) in male rats and on the estrous cycle in female rats.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-12"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First"></p>
<p>In two randomized, double-masked, multicenter, controlled clinical trials in which patients were dosed 3 times a day for 4 days, VIGAMOX® solution produced clinical cures on day 5-6 in 66% to 69% of patients treated for bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>. Microbiological success rates for the eradication of baseline pathogens ranged from 84% to 94%. Please note that microbiologic eradication does not always correlate with clinical outcome in anti-infective trials.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-13"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"></p>
<p>VIGAMOX® solution is supplied as a sterile ophthalmic solution in Alcon’s DROP-TAINER® dispensing system consisting of a natural low density polyethylene bottle and dispensing plug and tan polypropylene closure. Tamper evidence is provided with a shrink band around the closure and neck area of the package.</p>
<p>3 mL in a 4 mL bottle - NDC 0065-4013-03</p>
<p>Storage: Store at 2°C- 25°C (36°F - 77°F).</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-14"></a><p></p>
<h1>INFORMATION FOR PATIENTS</h1>
<p class="First"></p>
<p>Patients should be advised not to touch the dropper tip to any surface to avoid contaminating the contents.</p>
<p>Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>.</p>
<p>Systemically administered quinolones including moxifloxacin have been associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, even following a single dose. Patients should be told to discontinue use immediately and contact their physician at the first sign of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</p>
<p><span class="Bold">Rx Only</span></p>
<p>Licensed to Alcon by Bayer Pharma AG.<br>U.S. PAT. NO. 5,607,942; 6,716,830; 7,671,070<br>© 2003-2011 Novartis</p>
<p>Manufactured by<br>Alcon Laboratories, Inc.<br>Fort Worth, TX 76134 USA<br><br><span class="Bold">9007343-1011</span></p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
<p class="First">
    DRUG: VIGAMOX  </p>
<p><br></p>
<p>GENERIC: moxifloxacin hydrochloride</p>
<p><br></p>
<p>DOSAGE: SOLUTION</p>
<p><br></p>
<p>ADMINSTRATION: OPHTHALMIC</p>
<p><br></p>
<p>NDC: 61786-058-38</p>
<p><br></p>
<p>ACTIVE INGREDIENT(S):</p>
<ul><li>MOXIFLOXACIN HYDROCHLORIDE 5mg in 1mL</li></ul>
<p><br></p>
<p>INACTIVE INGREDIENT(S):</p>
<ul>
<li>BORIC ACID</li>
<li>HYDROCHLORIC ACID</li>
<li>SODIUM HYDROXIDE</li>
<li>SODIUM CHLORIDE</li>
<li>WATER</li>
</ul>
<p><br></p>
<p>PACKAGING: 3 mL in 1 BOTTLE, PLASTIC</p>
<p><br></p>
<p><br></p>
<p><br></p>
<p><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=750fd60e-c0c4-4f32-8301-6baa3516aef2&amp;name=MM2.jpg"></p>
<p><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=750fd60e-c0c4-4f32-8301-6baa3516aef2&amp;name=MM3.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VIGAMOX  		
					</strong><br><span class="contentTableReg">moxifloxacin hydrochloride solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:61786-058(NDC:0065-4013)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MOXIFLOXACIN HYDROCHLORIDE</strong> (MOXIFLOXACIN) </td>
<td class="formItem">MOXIFLOXACIN</td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61786-058-38</td>
<td class="formItem">3 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021598</td>
<td class="formItem">10/20/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ef311424-39d3-48fa-bc0f-d6fd413c7dc0</div>
<div>Set id: 750fd60e-c0c4-4f32-8301-6baa3516aef2</div>
<div>Version: 1</div>
<div>Effective Time: 20141020</div>
</div>
</div> <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
